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SUMMARY Aim:  To compare participation in breast, cervical and prostate cancer screening 
with colorectal cancer (CRC) screening. Materials & methods: This random digit-dialed 
survey includes participants (aged 50–75 years) from South Carolina (USA). Past participation 
information in fecal occult blood test, flexible sigmoidoscopy, colonoscopy, mammography, 
clinical breast examination, Pap test, prostate-specific antigen and digital rectal examination 
was obtained.Adjusted odds ratios are reported. Results: Among European–American 
women, any cervical or breast cancer screening was associated with adherence to any 
Practice points
 ●  Participation in colorectal cancer (CRC) screening lags behind screenings for other types of cancer (e.g., breast, 
cervical and prostate). Increasing participation in CRC screening is important to prevention and control of CRC, as 
CRC screening can be a form of primary cancer prevention.
 ●  CRC screening rates among African–Americans are typically lower than European–Americans. This disparity in 
screening is reflected in higher CRC incidence and mortality.
 ●  In our study, among European–American women, participation in breast and cervical cancer screenings was 
associated with participation in any type of CRC screening and specifically colonoscopy. These results were not 
consistent among African–American women.
 ●  Among all men, prostate-specific antigen tests and digital rectal examinations were associated with increased 
participation in colonoscopy.
 ●  Breast, cervical or prostate cancer screening tests can serve as ‘teachable moments’ to promote CRC screening in 
hopes of increasing participation.
 ●  Targeting these teachable moments using culturally appropriate strategies may help to overcome CRC-related 
barriers, such as fatalistic views or lack of knowledge and awareness, among minority populations.
 ●  ‘One-stop-shopping’ protocols for cancer screening may also help to increase participation in CRC screening.
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Colorectal cancer (CRC) is one of the most 
common and deadly types of cancer in the USA. 
CRC is the third most commonly diagnosed 
cancer among men and women [1]. Detection 
and removal of adenomatous polyps through 
colonoscopies can aid in early detection and 
primary prevention of CRC and greatly reduce 
mortality [2,3]. The US Preventive Services 
Task Force recommends men and women aged 
50 years and older to participate in CRC screen-
ing by having an annual fecal occult blood test 
(FOBT); a flexible sigmoidoscopy, double-con-
trast barium enema or computed tomography 
colonography every 5 years; or a colonoscopy 
every 10 years [3]. The Healthy People 2020 
goal for CRC screening adherence is 70.5% 
[4]. However, the estimated percentage of indi-
viduals adhering to CRC screening ranges 
from 47 to 66% depending on the data source, 
sex, race and ethnicity [5–10]. CRC screening 
is underutilized compared with screening for 
other types of cancer. For example, participa-
tion and adherence for cervical or breast cancer 
screening among women is reported as high as 
80% [7,9,11].
Racial disparities among many types of can-
cer and cancer screening, including CRC, have 
been observed and are likely a product of mul-
tiple, intersecting and complex causes [12]. Even 
after adjustment for sex, income, age and access 
to healthcare, which are factors that are typi-
cally associated with CRC screening among the 
general US population [13], African–Americans 
(AAs) still suffer disproportionately from 
lower rates of CRC screening [14]. Hébert et al., 
found a CRC mortality-to-incidence ratio, an 
indicator of survival that incorporates both 
incidence and mortality, among AAs of 0.418 
(95% CI: 0.390–0.447), whereas the mortal-
ity-to-incidence ratio was only 0.344 (95% CI: 
0.330–0.360) among European–Americans 
(EAs); this difference was statistically signifi-
cant [15]. Although rates of CRC screening are 
increasing in the USA, one possible explana-
tion for the racial differences in CRC incidence 
and mortality are racial disparities in CRC 
screening [4]. Studies, including those from the 
Behavioral Risk Factor Surveillance System 
(BRFSS), indicate increased prevalence or 
odds of CRC screening among EAs compared 
with AAs [4,6,7,16–17]. Additional examination 
of differences in screening for multiple types of 
cancer is warranted to elucidate strategies for 
intervention to increase participation among 
AAs or other racial and ethnic groups.
Basic demographic and socioeconomic fac-
tors, in addition to race, may not fully explain 
the difference in CRC screening between AAs 
and EAs [18]. Other factors, such as health 
insurance, medical care costs, physician recom-
mendation and regular contact with a medical 
system, are major factors that influence CRC 
screening participation, and for which AAs face 
greater financial or geographic barriers [4,8,19–26]. 
In addition, screening for breast, cervical or 
prostate cancer has been shown to be associ-
ated with CRC screening among several differ-
ent populations (e.g., EA, AA, Hispanic, male 
or female populations) [5,7,16–18,27–33]. However, 
not every study has found significant associa-
tions between CRC screening and other cancer 
screenings [18]. Carlos and colleagues suggest 
that using the setting of screening for one type 
of cancer can encourage and increase adherence 
for screening of another cancer type [34].
Of the studies that examined the relation-
ship between breast, cervical, prostate and CRC 
screening, none have examined both men and 
women and EAs and AAs, as well as utilized 
the number of cancer screening tests assessed 
(i.e., mammography, clinical breast examina-
tion, Pap test, prostate-specific antigen (PSA) 
test, digital rectal examination [DRE], colo-
noscopy, flexible sigmoidoscopy and FOBT) 
within the same population. The purpose of 
this study was to examine participation in 
breast, cervical or prostate cancer screening in 
comparison to participation in CRC screening, 
and to see if this comparison differed by race. 
We hypothesized that the odds of participation 
in mammography, clinical breast examinations 
or Pap tests among women, or PSA or DRE 
tests among men would be greater among those 
adhering to CRC screening recommendations 
compared with those who do not adhere to 
CRC screening.
CRC screening. Among African–American women, mammography was associated with 
adherence to any CRC screening. Digital rectal examination and prostate-specific antigen 
tests were associated with adherence to any CRC screening test among all men. Conclusion: 
Future research should explore approaches inclusive of cancer screening recommendations 
for multiple cancer types for reduction of cancer screening disparities.
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Materials & methods
●● Study population
A random-digit dialed telephone survey was 
conducted among men and women of CRC 
screening age (50–75 years) in South Carolina 
(SC; USA) from May to August of 2009. This 
cross-sectional, population-based telephone sur-
vey utilized automatically dialed landline and 
cellular telephone numbers with SC area codes 
provided by Survey Sampling Incorporated [4]. 
Surveys were administered by trained male and 
female interviewers through a professional sur-
vey research firm. To be eligible, men or women 
had to live in SC for the majority of the year; 
be of screening age; have no hearing, speak-
ing or cognitive difficulties that would pre-
clude completion of the telephone interview; 
and had to speak and understand English. If 
eligible respondents agreed to participate, they 
were asked a series of questions to confirm their 
understanding of what was expected of them and 
that participation was voluntary. This standard-
ized interview script for obtaining informed con-
sent is routinely used in telephone-based survey 
research and was approved by the University for 
South Carolina’s Institutional Review Board 
(SC, USA) [4]. Previously, using the same ran-
domly-digit dialed telephone survey, Brandt 
et al. found that increased CRC awareness and 
knowledge scores were statistically significantly 
associated with any CRC test (i.e., FOBT, flex-
ible sigmoidoscopy or colonoscopy) [4]. For the 
current analysis, there were a total of 1532 total 
respondents (36.6% response rate) with 29 par-
tially completed interviews that were excluded. 
After restricting the analysis to only EAs and 
AAs, which was self-reported, the final sample 
size of respondents with complete information 
for exposures and outcomes was 1237. This SC 
population represents a medically underserved 
population in which to examine participa-
tion in CRC screening, especially among AAs. 
Additional details on methodology are reported 
elsewhere [4].
●● Interview instrument & process
The instrument consisted of 144 self-reported 
questions assessing general health, awareness, 
knowledge and attitudes towards CRC screen-
ing, symptoms associated with increased CRC 
risk, past CRC and other cancer screening 
participation, exposure to CRC and screening 
information, access to healthcare and sociode-
mographic information. The instrument, which 
utilized questions previously used in cancer 
prevention and control throughout the nation 
and in SC, was developed based on a system-
atic literature review, external expert review and 
 multiphase testing [4].
●● Measures
The primary independent variables included 
participation in Pap tests, clinical breast exami-
nations and mammograms for women, and PSA 
and DRE tests for men. Specifically, respondents 
were asked to recall their participation in these 
cancer screenings within the past 12 months. 
Possible responses to each cancer screening test 
included ‘yes’, ‘no’, ‘don’t know’ or ‘refused’. 
Responses of ‘don’t know and ‘refused’ were 
removed from the analyses. Each cancer screen-
ing test was analyzed individually, as well as 
combined to create an ‘any cancer screening’ 
measure for men and women separately.
The main dependent variables were adherence 
to participation for each form of CRC screen-
ing (i.e., FOBT, flexible sigmoidoscopy and/or 
colonoscopy), as well as adherence to any form 
of CRC screening. Adherence was calculated 
using the participant’s current age, age at first 
screening and the screening type in the following 
equation, which was modified to fit each CRC 
screening test: If (current age) ≤ (age at first test 
+ [number of lifetime tests × number of years 
recommended between tests]) then the person 
was adherent. Self-reported ‘ever participating’ 
in any CRC screening test was also modeled as 
an outcome. Potential covariate data included 
urban/rural status, family/friend history of 
CRC, tobacco use, diet, health insurance, soci-
odemographic factors, access to healthcare, and 
several scores related to awareness, attitudes and 
knowledge of CRC that have been previously 
described [4].
●● Statistical analyses
Data were analyzed using SAS (version 9.3, 
NC, USA). χ2 tests for categorical variables and 
t-tests or Wilcoxon rank sums test for continu-
ous variables were used to compare descriptive 
population characteristics by race among men 
and women separately. Logistic regression vari-
able selection procedures were based on a series 
of bivariate analyses (i.e., exposure plus con-
founder). Variables were selected for further 
evaluation as potential confounders if their sta-
tistical significance was p ≤ 0.20. A backward 
elimination procedure was used to develop final 
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models that included all variables that were sta-
tistically significant (α ≤ 0.05) or, when removed 
from the model, changed the odds ratio of the 
primary independent variable by at least 10%. 
Rural/urban status was forced into all models due 
to the strong association between rural/urban 
status and CRC screening [35,36]. In addition, 
for several potentially important confounders 
(i.e., insurance, CRC awareness and knowledge 
scores) there was >10% missing information. 
These variables were not included in the vari-
able selection procedure. However, a sensitivity 
analysis for additional adjustment of these fac-
tors had little effect on the interpretability of the 
statistically significant findings. Unconditional, 
fixed-effects logistic regression was used to calcu-
late the adjusted odds ratio (aOR) and 95% CIs 
for the relationships between CRC screening 
or adherence and other cancer screenings after 
adjustment. By nature of the cancer screening 
tests, all analyses were stratified by sex. We 
a dditionally stratified all analyses by race.
Results
Overall, the respondents were primarily women 
(64%), EAs (79%), current or former smok-
ers (57%), married (61%), older (mean age: 
62.3 ± 7.2 years), overweight (mean BMI: 
28.4 ± 5.9), obtained at least some college educa-
tion (58%) or lived in urban areas (65%). There 
were several noticeable differences in population 
characteristics between EAs and AAs for both 
men and women (Table 1). EAs were more likely 
to have an undergraduate or graduate degree, 
have an income above US$50,000, be married, 
perceive their health as excellent or very good, 
drive themselves to healthcare, and to have higher 
CRC knowledge, awareness and attitude scores 
(all p-values ≤0.01) than AAs. Among men only, 
EAs were more likely to be employed than AAs 
(p = 0.01). EA women were more likely to live in 
urban areas, formerly or currently smoke, know 
someone with CRC, be older and have a lower 
BMI compared with AA women.
Table 2 displays the main results for men only. 
The odds of any prostate cancer screening test, 
PSA or DRE were 1.68 (95% CI: 1.05–2.66), 
2.05 (95% CI: 1.23–3.41) and 1.94 (95% CI: 
1.20–3.13), respectively, times greater among 
all men who were adherent to any CRC screen-
ing test compared with those who were not. 
Similar observations were noted for adherence 
to colonoscopy among all men. Among EA 
men, the odds of having a PSA test was 1.87 
(95% CI: 1.07–3.80) times greater among 
those who underwent a colonoscopy compared 
with those who did not. Additionally, PSA and 
DRE tests were statistically significantly associ-
ated with adherence to any CRC screening test. 
After adjustment, the only statistically signifi-
cant association observed among AA men was 
between any prostate cancer test (i.e., PSA or 
DRE) and adherence to colonoscopies (aOR: 
3.36; 95% CI: 1.04–10.17).
Statistically significant associations among all 
women mirrored findings among the EA female 
subgroup (Table 3). Among EA women, the odds 
of having undergone any cervical or breast can-
cer screening test was 3.23 (95% CI: 1.88–5.56) 
times more likely among those who had ever 
been screened for CRC compared with those 
who had not been screened for CRC. A similar 
relationship was observed individually for the 
clinical breast examinations and mammograms. 
For adherence to colonoscopy, we observed posi-
tive statistically significant associations for any 
cervical or breast screening examination (aOR: 
2.33; 95% CI: 1.41–3.84), as well as individu-
ally for clinical breast examination (aOR: 1.82; 
95% CI: 1.14–2.89) and mammography (aOR: 
2.61; 95% CI: 1.49–3.57). Similar findings were 
observed for adherence to any CRC screening 
test. Among AA women, the odds of a mam-
mography was 2.26 (95% CI: 1.07–4.74) times 
greater among those adhering to any CRC 
screening test compared with those who did 
not (Table 3). No other statistically significant 
associations were seen among AA women.
Discussion
This study examined the relationship between 
CRC screening and screening for other types of 
cancer (i.e., breast, cervical or prostate). Most 
statistically significant results were restricted 
to EA women, which were similar to findings 
observed among all women. Specifically, breast 
and cervical cancer screenings were associated 
with any previous CRC screening, as well as 
adherence to CRC screening. Mammography 
usage among AA women was also associated 
with greater adherence to colonoscopy screen-
ing. Our results among EA women were fairly 
consistent with previous research, although few 
of these studies exclusively examined EA or 
AA women [7,17,29,33]. For example, in a study 
by Carlos et al., both Pap test (aOR: 2.40; 
95% CI: 1.26–4.55) and mammography (aOR: 
3.42; 95% CI: 1.79–6.51) utilization predicted 
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Table 1. Descriptive statistics and other selected covariates by sex and race.
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Frequencies may not equal column total due to missing data. Column percentages may not equal 100% due to rounding. χ2 tests were used for comparison of categorical 
variables. T-tests or Wilcoxon rank sums tests were used for comparison of continuous measures. 
†’Do you plan to have a colonoscopy in the next 10 years?’. 
‡’Has anyone you know ever been diagnosed with colon cancer?’. 
§’How likely do you think it is you will develop colon cancer in the future?’. 
¶’How do you usually get to your healthcare provider?’. 
#Higher scores indicate a greater knowledge or awareness of CRC, or a more positive attitude toward CRC screening. 
CRC: Colorectal cancer.
Colorect. Cancer (2014) 3(3)258
ReSeARch ARticle Wirth, Brandt, Dolinger, Hardin, Sharpe & Eberth
future science group
any CRC screening adherence [7]. Among AA 
women, Reiter et al. found that those who 
reported a mammogram within the last year 
were more likely to be within any recom-
mended CRC screening guidelines (aOR: 3.25; 
95% CI: 1.28–8.28) [28]; whereas, the current 
study revealed mammography to be associated 
with only colonoscopy adherence among AA 
women. Our findings reveal potential racial 
disparities as they relate to CRC screening, 
which may partially explain racial disparities 
in CRC. According to the American Cancer 
Society, the incidence and mortality from CRC 
was higher among both male and female AAs 
compared with EAs [8]. Partially due to these 
known racial disparities in CRC, the American 
College of Gastroenterology currently recom-
mends that AAs begin CRC screening at the of 
age 45 years [37].
Regardless of race, we did not find breast or 
cervical cancer screening to be associated with 
FOBT or flexible sigmoidoscopy among female 
participants, which is inconsistent with previous 
research [30–31,38]. One possibility for this incon-
sistency is the limited sample size in the current 
study. Among female participants, numerous odds 
ratios were >1.0 for FOBT and flexible sigmoidos-
copy, but the CIs were wide and insignificant. In 
addition, small sample sizes among AA women 
may partially explain the lack of statistical signifi-
cance among this group, as aORs were of similar 
magnitude as EA women. We observed stronger 
associations between breast and CRC screening 
than for cervical and CRC screening. One pos-
sible explanation for this is that mammography 
and CRC both often require a visit beyond one’s 
primary care provider and these women may be 
more likely to adhere to multiple tests [5].
Among all men, our results were somewhat 
consistent with previous research [33,39–40], 
although there was inconsistency between EAs 
and AAs. We observed associations between PSA 
or DRE and adherence to any CRC screening test 
or adherence to colonoscopy, specifically, among 
all men. Carlos and colleagues found adherence 
to PSA (aOR: 3.24; 95% CI: 3.06–3.44) or 
DRE (aOR: 3.82; 95% CI: 3.60–4.06) were 
the strongest predictors of any CRC screening 
adherence using BRFSS data [16]. Haque and col-
leagues found that men who did not partake in 
PSA screening were statistically significantly less 
likely to partake in flexible sigmoidoscopy screen-
ing compared with those who did undergo PSA 
screening (aOR: 0.59; 95% CI: 0.56–0.63) [39], 
a result not observed in this study. Results among 
AA men may have been subject to reduced power 
due to limited sample sizes indicated by odds 
ratios >1.0, but imprecise and wide CIs.
Advantages of this study included use of men 
and women, as well as stratification by race. 
Few previous studies have exclusively focused 
on or stratified results by EAs and/or AAs [28]. 
Additionally, we analyzed participation in sev-
eral CRC screening tests including, FOBT, 
flexible sigmoidoscopy and colonoscopies. We 
compared these CRC screening tests to numer-
ous other cancer screening tests (mammography, 
clinical breast examination, Pap test, PSA and 
DRE), which is more inclusive than previous 
studies. The use of a SC population is unique 










Age (mean ± standard deviation) 62.1 ± 7.1 62.1 ± 7.5 0.94 63.0 ± 7.1 60.6 ± 7.0 <0.01
BMI (mean ± standard deviation) 28.7 ± 5.0 27.8 ± 5.1 0.16 27.5 ± 6.2 30.7 ± 6.5 <0.01
Knowledge score# (mean ± standard 
deviation)
11.0 ± 2.3 9.7 ± 2.6 <0.01 10.6 ± 2.1 9.6 ± 2.6 <0.01
Awareness score# (mean ± standard 
deviation)
3.0 ± 1.3 2.3 ± 1.4 <0.01 3.3 ± 1.2 2.4 ± 1.5 <0.01
Attitude score# (mean ± standard 
deviation)
11.2 ± 2.7 12.1 ± 3.0 0.01 11.0 ± 2.7 12.1 ± 2.8 <0.01
Frequencies may not equal column total due to missing data. Column percentages may not equal 100% due to rounding. χ2 tests were used for comparison of categorical 
variables. T-tests or Wilcoxon rank sums tests were used for comparison of continuous measures. 
†’Do you plan to have a colonoscopy in the next 10 years?’. 
‡’Has anyone you know ever been diagnosed with colon cancer?’. 
§’How likely do you think it is you will develop colon cancer in the future?’. 
¶’How do you usually get to your healthcare provider?’. 
#Higher scores indicate a greater knowledge or awareness of CRC, or a more positive attitude toward CRC screening. 
CRC: Colorectal cancer.
Table 1. Descriptive statistics and other selected covariates by sex and race (cont.).
259
Screening for breast, cervical & prostate cancer & colorectal cancer screening ReSeARch ARticle
future science group www.futuremedicine.com
considering that SC ranks in the highest quar-
tile of healthcare quality, but ranks among states 
with the largest income-related disparities in 
healthcare quality [41]. We were able to screen 
many known or suspected factors associated 
with cancer screening including, but not limited 
to, age, BMI, income, education, marital status, 
tobacco use, urbanicity, concerns/beliefs about 
CRC screening, knowledge/awareness of CRC, 
primary means of travel, healthcare utilization 
and insurance.
This study was subject to several limitations. 
The cross-sectional nature of this study precludes 
causation and it was not possible to determine 
if breast, cervical or prostate cancer screenings 
occurred prior to or after CRC screening or the 
direction of the relationship. Breast, cervical and 
prostate cancer screening participation was only 
obtained for the previous 12 months; whereas, 
CRC screening participation was obtained based 
on the recommended number of years between 
CRC screening tests. Of particular concern is 
bias related to Pap tests among women with a 
hysterectomy. The CDC and the US Preventive 
Services Task Force only recommends cervical 
cancer screening for women who have had a hys-
terectomy if they have a history of invasive cer-
vical disease [42]. Information on hysterectomy 
procedures and reason for hysterectomy were not 
obtained. Additionally, there is concern for recall 
bias due to the self-report nature of the interview. 
Although the sampling rate (36.6%) was similar 
to other computer-assisted telephone interviews 
[43], information on nonresponders was not col-
lected and therefore could not be compared with 
responders. Telephone interviewing protocols 
have inherent limitations [43,44], but methods 
were used to maximize participation, which have 
been described elsewhere [4]. Lastly, only AAs 
and EAs were examined; other minority groups 
were excluded due to small sample sizes.
Considering participation in breast and cervi-
cal cancer screening is greater than CRC screen-
ing participation [45], breast and cervical cancer 
Table 2. Association between colorectal cancer-related screening and other cancer screening tests among men.
Cancer 
screening test
All men European–American African–American
Crude OR (95% CI) Adjusted OR 
(95% CI)
Crude OR (95% CI) Adjusted OR 
(95% CI)
Crude OR (95% CI) Adjusted OR 
(95% CI)
Ever participating in any CRC screen test
Any cancer test 2.62 (1.64–4.19) 1.63 (0.98–2.74) 2.71 (1.61–4.55) 1.77 (0.99–3.14) 2.26 (0.76–6.75) 1.44 (0.41–5.06)
PSA 1.95 (1.14–3.32) 1.39 (0.78–2.48) 2.17 (1.19–3.97) 1.62 (0.84–3.19) 1.20 (0.38–3.98) 0.85 (0.23–3.19)
DRE 3.20 (1.97–5.20) 2.06 (1.21–3.51) 3.28 (1.92–5.61) 2.13 (1.18–3.85) 2.82 (0.87–9.16) 1.90 (0.52–7.02)
Adherence to colonoscopy
Any cancer test 2.76 (1.85–4.12) 1.71 (1.08–2.72) 2.54 (1.63–3.97) 1.44 (0.85–2.44) 3.67 (1.44–9.36) 3.36 (1.04–10.17)
PSA 2.43 (1.57–3.75) 1.87 (1.14–3.07) 2.55 (1.56–4.15) 1.87 (1.07–3.80) 2.00 (0.75–5.35) 1.42 (0.44–4.52)
DRE 2.74 (1.83–4.10) 1.79 (1.19–2.87) 2.65 (1.70–4.14) 1.60 (0.94–2.73) 2.90 (1.12–7.51) 3.21 (0.96–10.75)
Adherence to flexible sigmoidoscopy
Any cancer test 0.97 (0.57–1.64) 1.04 (0.61–1.77) 0.75 (0.41–1.39) 0.75 (0.40–1.38) 2.33 (0.79–6.86) 2.17 (0.72–6.56)
PSA 1.14 (0.67–1.96) 1.22 (0.70–2.10) 1.06 (0.56–2.00) 1.06 (0.56–2.00) 1.53 (0.53–4.42) 1.38 (0.47–4.08)
DRE 0.90 (0.53–1.54) 0.98 (0.57–1.68) 0.81 (0.43–1.53) 0.81 (0.43–1.52) 1.48 (0.52–4.26) 1.41 (0.48–4.15)
Adherence to fecal occult blood test
Any cancer test 1.48 (0.69–3.15) 1.59 (0.71–3.55) 1.77 (0.73–4.25) 1.82 (0.73–4.54) 0.74 (0.14–3.91) –
PSA 1.99 (0.99–4.03) 1.89 (0.91–3.91) 1.96 (0.90–4.24) 1.85 (0.83–4.11) 2.18 (0.41–11.68) –
DRE 2.00 (0.91–4.41) 2.20 (0.95–5.10) 2.11 (0.87–5.11) 2.23 (0.88–5.61) 1.50 (0.24–9.55) –
Adherence to any CRC screening test
Any cancer test 2.59 (1.72–3.90) 1.68 (1.05–2.66) 2.37 (1.50–3.74) 1.52 (0.90–2.57) 3.48 (1.35–8.97) 2.85 (0.88–9.20)
PSA 2.58 (1.62–4.11) 2.05 (1.23–3.41) 2.66 (1.58–4.49) 2.07 (1.17–3.67) 2.29 (0.82–6.41) 1.79 (0.50–6.41)
DRE 2.75 (1.82–4.17) 1.94 (1.20–3.13) 2.65 (1.67–4.20) 1.87 (1.10 -3.18) 3.02 (1.14–8.02) 2.72 (0.79–9.39)
Any CRC screening adjusted for age, plan on colonoscopy in next 10 years, health insurance, urban vs rural status and CRC awareness and attitude scores. Adherence to 
colonoscopy adjusted for age, plan on colonoscopy in next 10 years, know someone with CRC, employment status, income, urban vs rural status and CRC awareness and attitude 
scores. Adherence to flexible sigmoidoscopy adjusted for age and urban vs rural status. Adherence to fecal occult blood test adjusted for age, concern for CRC development, 
transportation means to clinic and urban vs rural status. Adherence to any CRC screening test adjusted for age, plan on colonoscopy in next 10 years, know someone with CRC, 
urban vs rural status, and CRC awareness, knowledge and attitude scores. 
–: Validity of model fit was questionable due to limited sample sizes. Any cancer test refers to any prostate cancer test (i.e., DRE or PSA); CRC: Colorectal cancer; DRE: Digital rectal 
examination; OR: Odds ratio; PSA: Prostate-specific antigen.
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screening tests may serve as ‘teachable moments’ 
to increase education of and participation in CRC 
screening. Carlos and colleagues suggest that an 
educational intervention for CRC screening that 
occurs at the time of other cancer screening tests 
may increase the effectiveness of the educational 
intervention. This, in turn, may increase partici-
pation in CRC screening [34]. Although BRFSS 
data indicate that CRC screening adherence is 
greater than prostate cancer adherence [6,45], PSA 
or DRE test visits can still be used as ‘teachable 
moments’. We further postulate that these ‘teach-
able moments’ may help to partially address racial 
disparities in CRC and CRC screening by help-
ing to overcome CRC screening barriers, espe-
cially among AAs. These barriers include, but 
are not limited to, socioeconomic status, access 
to healthcare, regular contact with the medical 
system, lack of health insurance, physician recom-
mendation and fatalistic views and knowledge 
about cancer screening [4,26,46–59]. These teachable 
moments may especially help to overcome racial 
barriers to CRC screening related to fatalist views 
or lack of knowledge and awareness about CRC. 
Additionally, coupling these ‘teachable moments’ 
with culturally targeted interventions, which have 
been shown to increase CRC screening participa-
tion [57,60–63], may further increase participation 
in CRC screening among minority populations.
Another approach to increasing CRC screen-
ing is through ‘one-stop-shopping’ for cancer 
screening [64]. The Integrated Cancer Prevention 
Center at the Tel Aviv Sourasky Medical Center 
(Tel Aviv, Israel) developed a protocol to test 
Table 3. Association between colorectal cancer-related screening and other cancer screening tests among women.
Cancer screening test All women European–American African–American
Crude OR (95% CI)  Adjusted OR 
(95% CI) 
Crude OR (95% CI)  Adjusted OR 
(95% CI) 
Crude OR (95% CI)  Adjusted OR 
(95% CI) 
Ever participating in any CRC screen test
Any cancer test 4.06 (2.71–6.10) 2.96 (1.85–4.71) 4.34 (2.71–6.96) 3.23 (1.88–5.56) 3.38 (1.51–7.58) 2.24 (0.88–5.75)
Pap smear 1.53 (1.07–2.20) 1.56 (1.03–2.37) 1.45 (0.95–2.21) 1.39 (0.85–2.27) 1.89 (0.94–3.80) 2.10 (0.90–4.91)
Breast examination 3.14 (2.13–4.61) 2.52 (1.63–3.91) 3.61 (2.31–5.64) 2.85 (1.71–4.73) 2.10 (0.97–4.52) 1.68 (0.68–4.15)
Mammography 3.38 (2.32–4.92) 2.26 (1.49–3.44) 3.72 (2.39–5.78) 2.53 (1.55–4.12) 2.61 (1.26–5.41) 1.76 (0.75–4.15)
Adherence to colonoscopy
Any cancer test 3.06 (2.10–4.46) 2.15 (1.40–3.30) 3.11 (2.01–4.79) 2.33 (1.41–3.84) 3.05 (1.40–6.68) 1.90 (0.78–4.65)
Pap smear 1.43 (1.06–1.93) 1.40 (0.98–1.99) 1.45 (1.02–2.06) 1.42 (0.93–2.15) 1.51 (0.83–2.74) 1.34 (0.67–2.68)
Breast examination 2.08 (1.47–2.92) 1.56 (1.05–2.32) 2.33 (1.57–3.46) 1.82 (1.14–2.89) 1.50 (0.76–2.99) 1.12 (0.50–2.52)
Mammography 3.07 (2.21–4.27) 2.13 (1.47–3.09) 3.25 (2.21–4.77) 2.61 (1.49–3.57) 2.70 (1.39–5.24) 2.07 (0.96–4.45)
Adherence to flexible sigmoidoscopy
Any cancer test 1.37 (0.74–2.54) 1.54 (0.82–2.90) 1.11 (0.54–2.26) 1.18 (0.69–2.02) 2.38 (0.68–8.33) 2.36 (0.67–8.29)
Pap smear 1.30 (0.83–2.03) 1.37 (0.87–2.17) 1.15 (0.68–1.97) 1.19 (0.68–2.07) 1.61 (0.71–3.65) 1.60 (0.70–3.62)
Breast examination 1.39 (0.80–2.43) 1.52 (0.87–2.68) 1.24 (0.64–2.41) 1.24 (0.64–2.41) 1.83 (0.66–5.10) 1.81 (0.65–5.05)
Mammography 1.23 (0.74–2.03) 1.32 (0.79–2.21) 1.04 (0.57–1.90) 1.05 (0.58–1.92) 1.82 (0.70–4.73) 1.82 (0.35–4.74)
Adherence to fecal occult blood test
Any cancer test 2.56 (1.01–6.51) 2.03 (0.78–5.27) 4.99 (1.19–20.92) 3.84 (0.90–16.37) 0.94 (0.25–3.51) 0.80 (0.20–3.17)
Pap smear 1.48 (0.86–2.55) 1.32 (0.76–2.29) 1.43 (0.76–2.66) 1.22 (0.64–2.30) 1.63 (0.54–4.89) 1.51 (0.49–4.69)
Breast examination 2.13 (0.99–4.57) 1.81 (0.83–3.96) 3.34 (1.18–9.49) 2.79 (0.96–8.10) 0.92 (0.28–3.02) 0.84 (0.24–3.89)
Mammography 1.57 (0.82–3.02) 1.33 (0.68–2.59) 2.54 (1.06–6.12) 2.11 (0.86–5.18) 0.61 (0.21–1.77) 0.53 (0.17–1.61)
Adherence to any CRC screening test
Any cancer test 3.57 (2.44–5.22) 2.60 (1.69–3.99) 3.82 (2.46–5.92) 2.93 (1.77–4.86) 3.00 (1.39–6.49) 2.15 (0.91–5.07)
Pap smear 1.60 (1.17–2.19) 1.59 (1.11–2.28) 1.61 (1.11–2.31) 1.59 (1.03–2.45) 1.72 (0.93–3.17) 1.55 (0.78–3.07)
Breast examination 2.49 (1.75–3.52) 1.93 (1.30–2.87) 2.90 (1.94–4.35) 2.31 (1.45–3.70) 1.60 (0.80–3.22) 1.32 (0.60–2.89)
Mammography 3.51 (2.50–4.91) 2.50 (1.72–3.64) 3.87 (2.61–5.74) 2.81 (1.80–4.39) 2.71 (1.40–5.27) 2.26 (1.07–4.74)
Any cancer test refers to any cervical or breast cancer test (i.e., Pap smear, clinical breast examination or mammography). Any CRC screening adjusted for age, plan on 
colonoscopy in next 10 years, health insurance, urban vs rural status and CRC awareness and attitude scores. Adherence to colonoscopy adjusted for age, plan on colonoscopy in 
next 10 years, know someone with CRC, employment status, income, urban vs rural status and CRC awareness and attitude scores. Adherence to flexible sigmoidoscopy adjusted 
for age and urban vs rural status. Adherence to fecal occult blood test adjusted for age, concern for CRC development, transportation means to clinic and urban vs rural status. 
Adherence to any CRC screening test adjusted for age, plan on colonoscopy in next 10 years, know someone with CRC, urban vs rural status, and CRC awareness, knowledge and 
attitude scores. 
CRC: Colorectal cancer; OR: Odds ratio.
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for colorectal, lung, breast, skin, prostate, ovary, 
uterine, cervix, testicular, oral and thyroid can-
cers. Tests for each of these cancers, excluding 
colonoscopies, were conducted on a single visit. 
This study found increased participation for 
numerous cancer screening tests compared with 
the general population of Israel [64]. Specifically 
for CRC, Sella et al. found that the ‘one-stop-
shopping’ protocol increased colonoscopy par-
ticipation by ≈144% compared with the general 
Israeli population (39 vs 16%) [64].
Conclusion & future perspective
CRC screening is vitally important for reduction 
of CRC incidence and mortality, as CRC screen-
ing can be a form of primary cancer prevention 
[8]. Cancer screening tests (e.g., mammography, 
clinical breast examination, Pap test, PSA and 
DRE) may help to promote CRC screening 
either through teaching moments or one-stop-
shopping. This may specifically address barri-
ers to CRC screening among AAs by increasing 
knowledge and awareness of CRC and through 
increasing access to cancer screenings, especially 
if these protocols are culturally appropriate. 
Future research should elucidate the relationships 
between CRC screening and other cancer screen-
ings, especially among minority populations, in 
terms of temporality. Additionally, ‘teachable 
moments’ or ‘one-stop-shopping’ interventions 
should be developed and applied among minority 
populations, such as AAs in southeastern USA, 
to determine if these protocols can  overcome 
racial barriers to CRC screening.
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